A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin.
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Sitagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 07 Jun 2017 Biomarkers information updated
- 01 Feb 2014 Results published in the Drugs and Aging.
- 02 Jun 2012 Company (InvaGen Pharmaceuticals) added to the associations field as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History